main content start

Video Shorts

Most Popular

Most Popular

Popular in No name
  • Breast Cancer3m 56s

    Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission

    There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.
    her2 positive mbc prolonged remission trastuzumab duration
  • Multiple Myeloma3m 12s

    Tips for Optimising Long Term Lenalidomide Maintenance in Multiple Myeloma

    Dr. Joseph Mikhael explains the triad of maintaining the patients on term Lenalidomide maintenance.
    long term maintenance therapy lenalidomide tips
  • Breast Cancer3m 44s

    Treating Brain Metastases of Breast Cancer

    Brain metastases are commonly observed in patients with Lung cancer, Breast Cancer & Melanoma. Breast Cancer patients are living longer & eventually develop Brain Metastases.
    brain metastases treatment
  • Breast Cancer3m 2s

    ESR1 Mutation as an emerging clinical biomarker metastatic hormone receptor positive Breast Cancer

    Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.
    biomarkers esr1 mutation fulvestrant hormone receptor positive mbc serd
  • Prostate Cancer3m 41s

    Whole genome sequencing in clinical practice

    Whole Genome Sequencing (Short)
    Whole Genome Sequencing is new tool for precision medicine in metastatic castration
    precision medicine prostate cancer whole genome sequencing
  • Myelodysplastic Syndromes2m 31s

    Duration of treatment does it improve outcomes Hypomethylating agents in MD

    Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.
    duration of treatment hypomethylating agents mds
  • Oncology3m 43s

    Cardio Oncology Issues in Lymphoma Management

    Newer treatments like immunotherapy are associated with myocarditis which has high fatality rates & cardiovascular issues arising of CART cell therapy are often attributed to Cytokine Release Syndrome (CRS).
    cytokine release syndrome lymphoma myocarditis
  • Myelodysplastic Syndromes2m 25s

    Factors that influence treatment adherence and outcomes in MDS

    Anticipate & manage adverse events to optimize treatment outcomes: Patients treated with hypomethylating agents are at increased risk of cytopenias & might need support with transfusions.
    adverse events hypomethylating agents mds treatment compliance
  • Multiple-Myeloma0m 53s

    Importance of identifying High Risk Patients in Multiple Myeloma

    High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.
    high risk myeloma
  • Oncology4m 9s

    Cardio Oncology in Prostate Cancer

    Major cardiovascular toxicities associated with the prostate cancer treatment include arrhythmias, atherosclerosis, myocardial Infarction, hypertension & cardiomyopathy. Toxicities vary with the type of agent used in Prostate Cancer Treatment.
    abcde protocol cardio oncology prostate cancer
  • Latest

    Latest

    Category Short Cards Listing

    All Videos

    All Videos

    Brightcove Tab Listing
    Sort by
    4m 12s
    Multiple Myeloma
    2m 41s
    OncoSpecials
    4m 19s
    Prostate Cancer
    2m 43s
    Multiple Myeloma
    2m 13s
    Prostate Cancer
    3m 43s
    Oncology
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback